HAE Treatment Options

WAO/EAACI 2018 Guidelines: Select Recommendations in Adults

In 2018, the World Allergy Organization (WAO) in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI) published an update and revision to their global guideline for HAE. An international expert panel was convened to review the existing evidence and developed 20 recommendations with the goal of providing clinicians and their patients with guidance that will assist them in making rational decisions in the management of Type 1 and Type 2 HAE. Read the full Guideline.

On-Demand Treatment: All Attacks Are Considered for On-demand Treatment

Early treatment with C1-INH concentrate, ecallantide, or Icatibant Injection provides a better treatment response than late treatment. Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity. As early treatment is facilitated by self-administration, all patients with HAE Types 1 or 2 should be considered for home therapy and self-administration training. All C1-INH concentrates and icatibant are licensed for self-administration, although approved product indications vary around the world.8 It is recommended that all patients have sufficient medication for on-demand treatment of two attacks and carry on-demand medication at all times.



Why Icatibant Injection?

Why Fresenius Kabi?


References

[8] 2018 Maurer – The international WAO_EAACI guideline for the management of hereditary angioedema – the 2017 revision and update REFERENCEvf1.14